 This is a phase II, multicenter, randomized, double-blind, placebo-controlled trial in which subjects with intermittent claudication IC will be randomized to receive a single treatment of VLTS-934 84 mL, or a total of 420 mg poloxamer 188 or placebo 84 mL saline administered as 21 intramuscular IM injections of 2 mL each, bilaterally into the lower extremities during one procedure to evaluate the safety, tolerability, and potential activity of VLTS-934 as compared with a saline placebo. 